Postconsolidation therapy consisting of the anti‐GD2 monoclonal antibody dinutuximab administered with the cytokines sargramostim (granulocyte‐macrophage colony‐stimulating factor [GM‐CSF]) and aldesleukin (IL‐2) and the differentiating agent isotretinoin has improved survival for newly diagnosed patients with high‐risk neuroblastoma (HR‐NBL).1, 2, 3. Here, IL2 is linked to neuroblastoma.